CHL1

Across TCGA pan-cancer cohorts, CHL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHL1 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CHL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHL1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where CHL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.408	1.000	.004	30	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	23	view →
PDAC	DFS	Median	II,III,IV	0.639	0.813	.010	12	view →
GBM	DFS	Median	All	0.842	0.651	.014	7	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →
LSCC	OS	Tertile	III,IV	1.000	0.538	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHL1–UCEC (OS)

Open the UCEC breakdown →